Alnylam's brezosiran reduced toxic huntingtin protein by 60-64% in spinal fluid, advancing to 2027 pivotal trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results